En Carta Diagnostics

Executive Summary

En Carta Diagnostics is a Paris-based biotechnology company founded in 2016 with a mission to develop innovative diagnostic solutions for infectious diseases, with a primary focus on Lyme disease. The company's proprietary technology aims to enable faster and more accurate detection, addressing a critical unmet need in Lyme disease diagnosis where current serological tests often fail to detect early-stage infections. En Carta operates in the competitive but high-growth infectious disease diagnostics market. While specific financial details and development stage are not publicly available, the company's niche focus on Lyme disease, which affects hundreds of thousands annually in Europe and North America, positions it for potential growth if it achieves regulatory milestones or partnerships. The company is private and has not disclosed funding rounds, limiting visibility into its operational progress.

Upcoming Catalysts (preview)

• Q2 2025CE Mark Approval for Lyme Diagnostic Test60% success
• Q4 2025Strategic Partnership with Diagnostic Distributor40% success
• Q1 2026Series A Funding Round Completion50% success